AMA approves CPT code for Axxent electronic brachytherapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 8
Volume 16
Issue 8

AMA approves CPT code for Axxent electronic brachytherapy

FREMONT, California—Xoft, Inc., maker of the FDA-approved Axxent Electronic Brachytherapy System (see Oncology NEWS International, June 2007, page 34) has announced that Axxent treatment now has a CPT reimbursement code. The American Medical Association CPT Editorial Panel approved the code (Category III CPT Code 0182T) for this novel form of high-dose-rate radiation therapy for the treatment of early-stage breast cancer. The code has been assigned a New Technology Ambulatory Payment Classification (APC), which secures payment for Medicare recipients who receive the treatment in the hospital outpatient setting.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.